MobilEye Global Inc vs Medtronic PLC — how do they compare? MobilEye Global Inc trades at $7.19 (market cap $6.00B), while Medtronic PLC trades at $87.7 (market cap $112.24B). The key difference: Medtronic PLC is far larger — about 18.7× MobilEye Global Inc's market cap, and Medtronic PLC pays a 3.28% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MobilEye Global Inc for 15 Days and Medtronic PLC for 63 Days on average.
| MBLY | MDT | |
|---|---|---|
Market Cap | $6.00B | $112.24B |
Volume | 7,007,849 | 105,663,236 |
Sector | Consumer Cyclical | Health |
52-Week High | $15.42 | $105.35 |
52-Week Low | $6.56 | $73.75 |
Typical Hold Time | 15 Days | 63 Days |
Enterprise Value | $4.56B | $131.58B |
Dividend Yield | — | 3.28% |
Signals from Pluang's Aura AI — not financial advice
Mobileye Global (MBLY) trades at $7.14, down 0.14% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $2.0B in 2026 but faces significant profitability challenges with a -201.49% net income margin. Analyst consensus is mixed with 57.7% buy ratings but a bearish technical outlook from indicators.
The stock presents a high-risk opportunity with substantial upside to the $10.83 consensus target but requires careful monitoring of profitability improvements. Key risks include persistent losses, competitive pressures in autonomous driving, and execution challenges in robotaxi expansion.
Medtronic (MDT) trades at $85.51, down 1.81% on the day, with the stock showing bearish technical signals despite strong fundamental performance. The company has beaten earnings expectations for three consecutive quarters, maintains a healthy 13.93% net income margin, and offers a solid 3.2% dividend yield with 49 consecutive years of dividend growth. Recent positive developments include FDA clearances for new medical technologies and raised full-year guidance.
MDT presents a compelling value opportunity with analyst consensus pointing to 14% upside to the $97.80 price target. The stock's current valuation multiples (P/E 21.61, P/S 3.01) appear reasonable given the company's stable revenue growth and strong cash flow generation. Key risks include increasing debt levels and competitive pressures in the medical device sector, but the company's dividend aristocrat status and improving operational performance support a positive long-term outlook.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →